[Path of a fighter]. / La désensibilisation allergénique au secours de la récidive.

Allergy is a frequent and often disabling condition for the patients. In the context of allergic rhinitis and asthma or anaphylactic shock to hymenoptera venom, allergenic desensitization can be proposed to limit the symptoms or recurrence of major reactions. Access to this treatment is made difficult by a lack of allergists, a lack of products or, more recently, by the Covid-19 crisis.

Post COVID-19 complications, adjunct therapy explored, and steroidal after effects

For COVID-19 survivors, defeating the virus is just the beginning of a long road to recovery. The inducibility and catastrophic effects of the virus are distributed across multiple organs. The induction of cytokine storms in COVID-19 patients is due to the interaction of the SARS-CoV-2 virus and the host receptor, leading to various immunopathological consequences that may eventually lead to death. So far, COVID-19 has affected tons of people across the world, but there is still no effective treatment. Patients facing complications of COVID-19 after recovery have shown extensive clinical symptoms similar to that of patients recovering from previously circulating coronaviruses. Previous knowledge and literature have opened up ways to treat this disease and manage post-COVID-19 complications, which pose a severe challenge to the health system globally and may exacerbate the fragmentation of diseases. The use of steroids as a treatment has resulted in various health problems and side-effects in COVID-19 patients. This review discusses various post-COVID-19 complications observed and adjunctive therapies used along with common COVID-19 treatment and spotlights their side effects and consequences. This review provides the latest literature on COVID-19, which emphasizes the subsequent complications in various organs, side effects of drugs, and alternative regimens used to treat COVID-19.Alternate :Pour les survivants de la COVID-19, vaincre le virus n’est que le début d’un long chemin vers la guérison. L’inductibilité virale et les effets catastrophiques qui en découlent sont disséminés dans plusieurs organes. L’induction de tempêtes de cytokines chez les patients atteints de COVID-19 est due à l’interaction entre le virus SRAS-CoV-2 et le récepteur de l’hôte, entraînant diverses conséquences immunopathologiques, susceptibles de mener ultimement à la mort. Jusqu’à présent, le virus a frappé des millions de personnes partout dans le monde, mais il n’existe toujours pas de traitement efficace. Les patients qui présentent des complications de la COVID-19 après leur convalescence ont manifesté de nombreux symptômes cliniques semblables à ceux provoqués par d’autres coronavirus ayant circulé auparavant. Les connaissances antérieures et la littérature ont ouvert une fenêtre sur des moyens de traiter la COVID-19 et de prendre en charge les complications qui surviennent après l’infection, lesquelles posent un grave problème pour le système de santé mondial et ont le potentiel de multiplier les déclinaisons de la maladie. L’utilisation de stéroïdes comme traitement a révélé divers problèmes de santé et effets secondaires chez les patients atteints de la COVID-19. Cette revue de littérature dresse un portrait détaillé des diverses complications post-COVID-19 observées et des traitements adjuvants utilisés en association avec les médicaments couramment employés pour traiter la COVID-19, et met en évidence leurs effets secondaires et leurs conséquences. L’article offre une synthèse de la plus récente littérature sur la COVID-19, qui se concentre sur les complications subséquentes touchant divers organes, les effets secondaires des médicaments et les autres traitements qui ont été utilisés contre cette maladie. [Traduit par la Rédaction]

[Immunotherapy adaptation in lung cancer during the COVID-19 pandemic]. / COVID-19 et cancer bronchique : adaptation des schémas d'immunothérapie et qualité de vie.

INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400mg every 6weeks, nivolumab to 480mg every 4weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the tolerance, of this new schedule. METHODS: Thoracic oncologic patients who underwent these therapeutic changes in our center during the first COVID-19 epidemic wave were included. Their quality of life was assessed using the Quality of Life Questionnaire-30, their psychological state by the Hospital Anxiety Depression (HAD) scale. We also reported the preferred administration schedule, as well as adverse events. RESULTS: Thirty patients were included. The overall quality of life was preserved. Rates on HAD scale were low. Tolerance was acceptable. In majority, patients preferred the new procedure. They had a significantly better quality of life compared to those who preferred the old one. CONCLUSIONS: This new immunotherapy schedule in thoracic oncology is well tolerated and allows a preservation of quality of life. This therapeutic option may be favored in the context of COVID-19 pandemics.